logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Mrna Therapeutics Fasttomarket Strategies Sarfaraz K Niazi

  • SKU: BELL-46653420
Mrna Therapeutics Fasttomarket Strategies Sarfaraz K Niazi
$ 31.00 $ 45.00 (-31%)

0.0

0 reviews

Mrna Therapeutics Fasttomarket Strategies Sarfaraz K Niazi instant download after payment.

Publisher: CRC Press
File Extension: PDF
File size: 40.68 MB
Pages: 325
Author: Sarfaraz K. Niazi
ISBN: 9781032163444, 9781032163482, 1032163445, 1032163488
Language: English
Year: 2022

Product desciption

Mrna Therapeutics Fasttomarket Strategies Sarfaraz K Niazi by Sarfaraz K. Niazi 9781032163444, 9781032163482, 1032163445, 1032163488 instant download after payment.

This book is the most comprehensive and complete treatise on nucleic acid therapeutic
products, including mRNA vaccines, their manufacturing, formulations, and
testing for safety and efficacy. Details include cGMP-compliant manufacturing and
regulatory filing steps. A new concept of “biosimilar” mRNA vaccine is presented
to secure fast approval of copies of mRNA vaccines. Projections of financial plans
to establish RNA manufacturing facilities are provided, along with details of supply
chain management. Finally, the future of nucleic acid products in gene therapy and
other newer applications is presented, along with a perspective that all new vaccines
will be the nucleic acid type that will further provide first-time prevention of autoimmune
disorders. It is projected that both big pharma and start-ups will enter this field,
and we can expect significant additions to our drug armamentarium soon.

Related Products